Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

Dow Jones10-03
 

2242 GMT [Dow Jones]--Forsyth Barr lays out two reasons why it's pleased with Synlait Milk's sale of its North Island assets to health care company Abbott for NZ$307 million. The deal removes risk to Synlait's balance sheet. Forsyth Barr estimates Synlait will be net cash in FY 2026. Secondly, the transaction eliminates material losses, given the North Island assets had a NZ$20 million drag on Ebit in FY 2025. "It has served as a sharp lesson in the value of disciplined capital allocation," analyst Matt Montgomerie says. "We are glad this journey is over." Forsyth Barr upgrades Synlait to neutral, from underperform. Synlait is unchanged at NZ$0.835 today. (david.winning@wsj.com)

 

(END) Dow Jones Newswires

October 02, 2025 18:46 ET (22:46 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment